Adjuvant activity of type I interferons

dc.contributor.authorTovey, M. G.en
dc.contributor.authorLallemand, C.en
dc.contributor.authorThyphronitis, G.en
dc.date.accessioned2015-11-24T16:34:07Z
dc.date.available2015-11-24T16:34:07Z
dc.identifier.issn1431-6730-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/7760
dc.rightsDefault Licence-
dc.subjectadjuvanten
dc.subjectapoptosisen
dc.subjectcytokinesen
dc.subjectinterferonsen
dc.subjecttoll-like receptor (tlr)en
dc.subjectvaccinationen
dc.subjectquality-of-lifeen
dc.subjectt-cellsen
dc.subjectdendritic cellsen
dc.subjectsignaling pathwaysen
dc.subjectdirect stimulationen
dc.subjectadaptive immunityen
dc.subjectinfluenza vaccineen
dc.subjectviral-infectionen
dc.subjectifn-alphaen
dc.subjectphase-iien
dc.titleAdjuvant activity of type I interferonsen
heal.abstractType I interferons (IFNs) produced primarily by plasmacytoid dendritic cells (pDCs) as part of the innate immune response to infectious agents induce the maturation of myeloid DCs and enhance antigen presentation. Type I IFNs also enhance apoptosis of virus-infected cells, stimulate cross priming and enhanced presentation of viral peptides. Type I IFNs are powerful polyclonal B-cell activators that induce a strong primary humoral immune response characterized by isotype switching and protection against virus challenge. Type I IFNs stimulate an IgG2a antibody response characteristic of Th1 immunity when ad-mixed with influenza virus vaccine and injected intramuscurarly (i.m.) or administered intranasally. The adjuvant activity of type I IFNs has been shown to involve direct effects of IFN on B-cells, effects on T-cells, as well as effects on antigen presentation. Oromucosal administration of type I IFNs concomitantly with i.m. injection of vaccine alone can also enhance the antibody response to influenza vaccination by enhancing trafficking of antigen-presenting cells towards the site of vaccination. Recombinant IFNs are potent adjuvants that may find application in both parenterally and mucosally administered vaccines.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primaryDoi 10.1515/Bc.2008.051-
heal.identifier.secondary<Go to ISI>://000255439000009-
heal.identifier.secondaryhttp://www.degruyter.com/dg/viewarticle.fullcontentlink:pdfeventlink/contentUri?t:ac=j$002fbchm.2008.389.issue-5$002fbc.2008.051$002fbc.2008.051.xml-
heal.journalNameBiol Chemen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2008-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιώνel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Πρωτότυπος φάκελος/πακέτο

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
Tovey-2008-Adjuvant activity of.pdf
Μέγεθος:
74.45 KB
Μορφότυπο:
Adobe Portable Document Format

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Φόρτωση...
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή: